Organon & Co. (OGN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | (m) | |
| Revenue | 6.13B USD | |
| Cost of products and services | 2.90B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 1.71B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.13B | $2.90B | (m) | $1.71B | (m) |
| 2026-03-31 | (m) | $6.16B | $2.91B | (m) | $1.73B | (m) |
| 2025-12-31 | (m) | $6.22B | $2.90B | (m) | $1.72B | (m) |
| 2025-09-30 | (m) | $6.30B | $2.83B | (m) | $1.76B | (m) |
| 2025-06-30 | (m) | $6.28B | $2.75B | (m) | $1.76B | (m) |
| 2025-03-31 | (m) | $6.29B | $2.69B | (m) | $1.75B | (m) |
| 2024-12-31 | (m) | $6.40B | $2.69B | (m) | $1.76B | (m) |
| 2024-09-30 | (m) | $6.41B | $2.67B | (m) | $1.76B | (m) |
| 2024-06-30 | (m) | $6.35B | $2.63B | (m) | $1.88B | (m) |
| 2024-03-31 | (m) | $6.35B | $2.60B | (m) | $1.89B | (m) |
| 2023-12-31 | (m) | $6.26B | $2.52B | (m) | $1.89B | (m) |
| 2023-09-30 | (m) | $6.15B | $2.43B | (m) | $1.89B | (m) |
| 2023-06-30 | (m) | $6.17B | $2.37B | (m) | $1.80B | (m) |
| 2023-03-31 | (m) | $6.14B | $2.31B | (m) | $1.77B | (m) |
| 2022-12-31 | (m) | $6.17B | $2.29B | (m) | $1.70B | (m) |
| 2022-09-30 | (m) | $6.29B | $2.30B | (m) | $1.72B | (m) |
| 2022-06-30 | (m) | $6.36B | $2.36B | (m) | $1.66B | (m) |
| 2022-03-31 | (m) | $6.37B | $2.35B | $472.00M | $1.66B | (m) |
| 2021-12-31 | (m) | $6.30B | $2.38B | $443.00M | $1.67B | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $6.53B | $2.12B | $210.00M | $1.36B | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $7.78B | $2.27B | $220.00M | $1.44B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |